| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.13 | 0.07 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.065 | 0.07 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.065 | 0.08 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.08 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.08 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.06 | 0.08 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | 0.073 | 0.08 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.08 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.08 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.09 |